Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity.
Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity.
复制标题
DOI：
10.1155/2011/835410
复制
发表时间：
2011-01-01
影响因子：
--
通讯作者：
Actor, Jeffrey K
中科院分区：
文献类型：
--
作者：
Hwang, Shen-An;Welsh, Kerry J;Actor, Jeffrey K
接种疫苗预防结核病的目的是为个人和社区提供长期保护。此外，任何保护性结核病疫苗的成功应该包括限制空洞形成和疾病进展的能力。目前的卡介苗通过促进抗原特异性反应的发展来保护儿童免受播散性结核病的侵害。然而，其在预防成人原发后肺部疾病方面的疗效有限，而成人原发后肺部疾病是大多数疾病和传播的原因。本文阐述了使用乳铁蛋白作为佐剂，以提高卡介苗的效力，以控制有机体的生长和限制肺部疾病的严重表现。这种病理学上的限制可能最终限制杆菌的传播和随后的个体间生物体的传播。目前的文献进行了审查，并提出数据支持的分子机制乳铁蛋白的效用作为卡介苗的佐剂。
The goal of vaccination to prevent tuberculosis disease (TB) is to offer long-term protection to the individual and the community. In addition, the success of any protective TB vaccine should include the ability to limit cavitary formation and disease progression. The current BCG vaccine protects against disseminated TB disease in children by promoting development of antigenic-specific responses. However, its efficacy is limited in preventing postprimary pulmonary disease in adults that is responsible for the majority of disease and transmission. This paper illustrates the use of lactoferrin as an adjuvant to boost efficacy of the BCG vaccine to control organism growth and limit severe manifestation of pulmonary disease. This resulting limitation in pathology may ultimately, limit spread of bacilli and subsequent transmission of organisms between individuals. The current literature is reviewed, and data is presented to support molecular mechanisms underlying lactoferrin's utility as an adjuvant for the BCG vaccine.